COMP <GO>
SANG vs HCAT // EV/EBITDA & P/E VALUATION
Sangoma Technologies Corporation (NASDAQ) VS. Health Catalyst Inc (NASDAQ) • 15-METRIC TALLY: SANG 2
— HCAT 0
■ METRIC PARITY
LAST: $4.71 (+1.07%) • MKT CAP: $157.9M
valuation
—
LAST: $1.79 (-0.56%) • MKT CAP: $134.7M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SANG VS. HCAT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SANG | HCAT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -35.00% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -0.18% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -51.70% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -57.20% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 1.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 4/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.4 | 46.8 | +9.64 | SANG | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $157.9M | $134.7M | $23.1M | SANG | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SANG REV | HCAT REV | SANG GROSS % | HCAT GROSS % | SANG FCF | HCAT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $311.1M | — | — | — | -$237.0K |
| FY 2024 | — | $306.6M | — | — | — | $12.9M |
| FY 2023 | — | $295.9M | — | — | — | -$33.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SANG // BETA —
HCAT // BETA —